Precision Medicine in Prostate Cancer: Multidisciplinary Perspectives in Identifying, Managing and Optimizing Patient Care (English)

Canadian Urological Association (CUA)

English - November 18, 2021 05:00 - 1 hour - 63.1 MB
Medicine Health & Fitness Science Life Sciences medicine urologic urology Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Precision Medicine in Prostate Cancer: Multidisciplinary Perspectives in Identifying, Managing and Optimizing Patient Care (French)

Next Episode: Management of Medication-Refractory Overactive Bladder (OAB)

Disclosures:

Neil Fleshner
Payment: Astellas, Janssen, Abbvie, Sanofi, Merck
Grant/Honorarium: Astellas, Janssen, Bayer
Investments: Verity Pharma
Clinical Trials: Astellas, Janssen, Bayer
Leadership Position: Point Biopharma

Urban Emmenegger
Advisory Boards: Amgen, Astellas, Bayer, Ferring, Janssen, Sanofi, Merck, AstraZeneca
Payment: Astellas, Bayer, Ferring, Janssen, Sanofi, Merck, AstraZeneca
Grant/Honorarium: Amgen, Astellas, Bayer, Ferring, Janssen, Sanofi, Merck, AstraZeneca
Clinical Trials: AstraZeneca, Bayer, Clovis, Janssen, Merck, Roche

Emily Thain
Advisory Boards: AstraZeneca/Merck, Pfizer
Honorarium: AstraZeneca/Merck, Pfizer